AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00673738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: * Cetuximab dose: based on patient's actual weight. Loading phase dose of cetuximab is 400 mg/m2 IV administered over 120 minutes, on day 1 followed by; Concurrent phase, weekly infusion dose at 250 mg/m2 IV over 60 minutes, on days 8, 15, 22, 29, 36, 43, 50.~* Radiation will be accompanied by weekly Cetuximab. Weekly Cetuximab will start on 1st day of radiation (Day 8). So, total number of cetuximab administrations will vary from 7 to 8. Patients will have every other week complete blood counts (CBCs), differentials, and blood urea nitrogen (BUN) plus creatinine and Mg. If patient's ANC drops below 1,000 and/or the platelet count below 75,000 during CTRT, the corresponding, weekly dose of cetuximab will be omitted.
Study NCT00673738 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Conformal Thoracic Radiotherapy (CTRT)
Description: * Radiation will be accompanied by weekly Cetuximab. Weekly Cetuximab will start on 1st day of radiation (Day 8). So, total number of cetuximab administrations will vary from 7 to 8. Patients will have every other week CBCs, differentials, and BUN plus creatinine and Mg. If patient's ANC drops below 1,000 and/or the platelet count below 75,000 during CTRT, the corresponding, weekly dose of cetuximab will be omitted.~* Radiation therapy will begin on day 8 (with window of ± 3 days). Adequate hematologic profile (ANC >1,000 and platelets >75,000) required. Patient may be delayed for a max. of 2 weeks. If > 2 week delay occurs, patient will come off study.
Study NCT04643613 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protison cancer nutritional formula (PCNF)
Description: PCNF (237 mL/Pack) for 5-6 times/day via bolus NG tube feeding for 12 weeks
Study NCT00404222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodone/Acetaminophen Extended-Release
Description: 2 tablets x 1
Study NCT00404222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocodone/Acetaminophen Immediate Release (NORCO®)
Description: 1 tablet q 4 hours x 3
Study NCT00404222 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: q 4 hours x 3
Study NCT03035357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: 16 mg/kg by vein once weekly for a total of 4 doses.
Study NCT02185495 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Observer nodule detection
Description: Radiologists will detect the nodules.
Study NCT02185495 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computer-aided nodule detection
Description: Computed-aided detection (CAD) software will be used to detect the nodules.
Study NCT02324348 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deferred coronary stenting
Description: Abciximab (0.25㎎/㎏) intracoronary injection will be performed to all possible patients after guidewire has passed culprit lesion. Additional manual thrombus aspiration or balloon angioplasty can be performed by operator to achieve TIMI Ⅲ flow. When TIMI Ⅲ flow is achieved after these procedures, patient will be randomized to immediate stenting or deferred stenting group. In deferred stenting group, second stage procedure (stent implantation) will be done at 5 to 7 days after TIMI Ⅲ flow has achieved.
Study NCT02324348 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Immediate coronary stenting
Description: Abciximab (0.25㎎/㎏) intracoronary injection will be performed to all possible patients after guidewire has passed culprit lesion. Additional manual thrombus aspiration or balloon angioplasty can be performed by operator to achieve TIMI Ⅲ flow. When TIMI Ⅲ flow is achieved after these procedures, patient will be randomized to immediate stenting or deferred stenting group. In immediate stenting group, stenting will be done immediate after achieving TIMI III flow during initial procedure.
Study NCT03590041 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standardized SMA
Description: Patients receiving the Standardized SMA intervention will be part of group visits that cover a modified TTIM 6-session curriculum, delivered only by health educators. The Standardized SMA approach will be uniformly administered at each practice. Topics will be covered in a predetermined order and patients will not have a say in terms of what content they wish to cover. Patients receive the Standardized SMA approach if their practice is randomly assigned to the Standardized SMA arm. Practices are cluster-randomized to deliver a standardized or patient-driven group visit model.
Study NCT03590041 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient-driven SMA
Description: Patients receiving the Patient-driven SMA intervention will be part of group visits that cover a modified TTIM 6-session curriculum, but patients are in control of time spent and order of the topics. The Patient-driven SMA will be delivered by a multidisciplinary team consisting of a Health Educator, medical provider, Behavioral Health Professional, and a diabetes peer mentor. Patient-driven SMAs may be delivered differently at each practice, as patients choose the topics that are most important to spend the most time on. All topics will be covered, but the order and time spent is up to the group. Patients receive the Patient-driven SMA approach if their practice is randomly assigned to that arm. Practices are cluster-randomized to deliver a standardized or patient-driven SMA model.
Study NCT04396639 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Moroctocog-alfa (AF-CC)
Description: Moroctocog-alfa (AF-CC) is indicated for the control and prevention of hemorrhagic episodes and for routine and surgical prophylaxis in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia).
Study NCT04285970 — intervention group
Intervention type: OTHER
Intervention: cycle detection
Description: 6-minute test on a treadmill at pedestrian speed (5km/h) with 2 instruments (dynamometric wheel and inertial centre) on a standardised wheelchair
Study NCT04285970 — intervention group
Intervention type: OTHER
Intervention: detection of effort intensity
Description: 6-minute test on an urban course with 2 instruments (dynamometric wheel and inertial units) on a wheelchair
Study NCT02790892 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Art therapy - pre and post test measures
Description: 12 weeks of 90 minutes of art therapy with pre and post test measures to determine changes in social support and levels of diabetes distress
Study NCT00087867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCIO-469
Description: two 30-mg capsules three times daily
Study NCT00087867 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: SCIO-469 and bortezomib
Description: In addition to SCIO-469, patients with disease progression will receive bortesomib 1.0 mg/m2 intravenously as a bolus injection on Days 1, 4, 8, and 11 of a 21-day cycle, followed by a 10-day rest period
Study NCT04516889 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Doubled sutured SFIOL
Description: Recruited subjects would undergo implantation of SFIOL with the modified technique under either local or general anesthesia. The surgeon would mark the sclerotomies as per routine sutured SFIOL at 2mm behind the nasal and temporal limbus, followed by passage of 2 pairs of prolene sutures. The intraocular lens with islets would be implanted into the posterior chamber and sutured to the sclera as per single suture SFIOL.
Study NCT02740023 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hearing Aid (Phonak Audéo V90-13)
Description: Phonak's Receiver-In-the-Canal (RIC) hearing aid Audéo V90-13 will be fitted to the participants individual Hearing loss.
Study NCT02740023 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing Aid (Successor of Phonak Audéo V90-13)
Description: The successor of Phonak's Receiver-In-the-Canal (RIC) hearing aid Audéo V90-13 will be fitted to the participants individual Hearing loss.
Study NCT04277338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPECT
Description: One single injection of 99mTc-HE3-G3, followed by gamma camera imaging directly postinjection and after 2, 4, 6 and 24 hours.
Study NCT01082068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL147 (SAR245408)
Description: given orally once daily as tablets
Study NCT01082068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL765 (SAR245409)
Description: given orally twice daily as capsules
Study NCT01082068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole (Femara)
Description: given orally once daily as tablets
Study NCT00885170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odanacatib
Description: Odanacatib 50 mg tablets once weekly for 24 months
Study NCT00885170 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to odanacatib 50 mg tablets once weekly for 24 months
Study NCT00885170 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3, two 2800 IU tablets, taken once weekly for 24 months
Study NCT00885170 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D3, two 2800 IU tablets, taken once weekly for 24 months
Study NCT00885170 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium
Description: Participants will receive calcium carbonate supplements as needed to ensure a daily calcium intake of 1200 mg.
Study NCT00885170 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium
Description: Participants will receive calcium carbonate supplements as needed to ensure a daily calcium intake of 1200 mg.
Study NCT02282098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Colchicine 0.6mg twice daily
Study NCT02282098 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Colchicine
Study NCT01312103 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based safety decision aid
Description: Participants will log into the the intervention website at baseline, 3 months, 6 months, and 12 months post baseline and receive:~* Setting of priorities for safety; a sliding bar allows participants to establish priorities by making pairwise comparisons of importance between factors.~* Danger Assessment; asks women to report on well-established risk factors for repeat violence and lethal IPV. A weighted scoring algorithm provides participants with their validated level of danger.~* Personalized action plan. Based on a participant's answers to the previous sections, a list of safety strategies with links to resources will be presented to her. The participant is given the option to print her results and the personalized plan.
Study NCT01312103 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Safety Plan
Description: Participants will log into a control website at baseline, 3 months, 6 months and 12 months post baseline. Website will include the usual services provided to IPV survivors looking for safety planning resources on the internet. Participants will receive:~* Danger Assessment, will see risk factors associated with lethal violence, but will not receive a score or feedback.~* A brief emergency safety plan with links to national and state domestic violence resources as well as a suicide resource.
Study NCT04485390 — intervention group
Intervention type: OTHER
Intervention: Basic life support witn use of an AED before EMS
Description: BLS performance with use of an AED before arrival of EMS
Study NCT01460693 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib
Description: Oral Imatinib 100mg daily
Study NCT01460693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Oral Dasatinib 100mg daily
Study NCT03994848 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spirometry Group
Description: Patients that are provided the incentive spirometer pre-operatively and instructed to use it for 4 cycles of 10 spirometry attempts on the day prior to surgery
Study NCT04178603 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise, insulin infusion
Description: Trial A: Acute one-legged exercise Trial B: Insulin infusion 4 hours after one-legged exercise
Study NCT04001322 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community engagement
Description: The government will conduct a cascade of sensitization meetings with traditional leaders at all levels to promote newborn line listing (birth registration), reconciliation of child's vaccination status and defaulter tracking (home-based follow up of children who have missed their vaccination doses) by health providers and community leaders
Study NCT04001322 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Community engagement
Description: The government will conduct a cascade of sensitization meetings with traditional leaders at all levels to promote newborn line listing (birth registration), reconciliation of child's vaccination status and defaulter tracking (home-based follow up of children who have missed their vaccination doses) by health providers and community leaders
Study NCT04001322 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IRISS advert for opt-in
Description: A module to advertise and demonstrate how individuals can opt-in to IRISS to receive the messages will be included in the community engagement sensitization meetings.
Study NCT04001322 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: One-time SMS broadcast on immunization
Description: General broadcast of SMS messages on the importance of immunization to all active mobile phone subscribers in the intervention LGAs
Study NCT04001322 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scheduled weekly SMS reminder of health facility RI schedule to community leaders
Description: Traditional and religious leaders who have a phone or access to a phone and have been registered on IRISS will receive SMS messages on the immunization session schedule of the health facilities in their communities, so they can disseminated the information through their town announcers to inform parents and caregivers. For example, Ribah clinic is holding a vaccination session tomorrow from 8am to 2pm. Please take your child there to vaccinate them and encourage your neighbors to vaccinate their children.
Study NCT04001322 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scheduled bi weekly RI messages to community leaders
Description: Traditional and religious leaders who own or have access to a phone and have been registered on IRISS will receive SMS messages on immunization, to share same with community members. The message categories are: 1) Educational messages that provide facts and increase knowledge, e.g. Have you heard of Penta vaccine? It protects against 5 diseases: they are diphtheria, whooping cough, tetanus, HiB and Hepatitis B. 2) Informative messages that dispel myths about immunization, e.g. Getting more than one vaccine at the same time does not harm a child. It is very important to completely receive all vaccine doses for full protection. 3) Normative messages to promote positive norms, e.g. Our religious leaders have immunized their children, what are we waiting for? 4) Motivational messages to inspire action, e.g. Each visit to the health center for vaccination will reap many health benefits. Say YES to good health, be on time and complete your child's vaccination.
Study NCT04001322 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Responsive individualized child vaccination schedule reminder to caregivers who opt-in
Description: Parents and caregivers who voluntarily registered their child's information into IRISS will receive a reminder, a day before, about their child's due vaccines and the schedule of vaccination sessions in the health facilities within their locality (wards), e.g. Greetings! Amina is due for Penta 1 tomorrow, kindly visit Ribah clinic. They vaccinate on Mondays and Thursdays.
Study NCT04001322 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Responsive one-time SMS message on hand washing to those that erroneously register on IRISS
Description: If individuals from control LGAs encounter IRISS adverts inadvertently and erroneously register into IRISS expecting a message, to avoid a loss in trust if no message is sent, they will receive a one-time general message about the importance of hand-washing, e.g. Wash your hand with soap and water every time you finish from to the toilet, to maintain clean hands and avoid germs that make you sick.
Study NCT02688777 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Backward Walking Training
Description: Backward Walking Training will occur both on a treadmill and overground. In brief, BWTraining will consist of 20-30 minutes of step training with a Body Weight Support and Treadmill system (BWST), rest periods provided as warranted, with manual assistance provided by trainers, followed by 15 minutes of overground gait training. A 20-30 min period of actual stepping is the goal for the intervention sessions on the treadmill with rest periods as needed. Each training session may last up to 1 hour and 30 minutes including time for warm-up, stretching, and cool down. Participants will be fitted with a harness around their hips and torso, which will be attached to an overhead support system directly above the treadmill. From a stationary position, the treadmill belt will gradually be increased in speed with intervention trainers assisting participant to step backward with their paretic leg, their non-paretic leg (if needed) and at the hips for weight-shift.
Study NCT02688777 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Backward Walking Training
Description: Backward Walking Training will occur both on a treadmill and overground. In brief, BWTraining will consist of 20-30 minutes of step training with a Body Weight Support and Treadmill system (BWST), rest periods provided as warranted, with manual assistance provided by trainers, followed by 15 minutes of overground gait training. A 20-30 min period of actual stepping is the goal for the intervention sessions on the treadmill with rest periods as needed. Each training session may last up to 1 hour and 30 minutes including time for warm-up, stretching, and cool down. Participants will be fitted with a harness around their hips and torso, which will be attached to an overhead support system directly above the treadmill. From a stationary position, the treadmill belt will gradually be increased in speed with intervention trainers assisting participant to step backward with their paretic leg, their non-paretic leg (if needed) and at the hips for weight-shift.
Study NCT03066947 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SV-BR-1-GM
Description: See above
Study NCT03066947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Low dose pre-treatment to reduce regulatory T cells
Study NCT03066947 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interferon-alpha-2b
Description: Low dose given in the vaccine site to boost the immune response
Study NCT02718144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estetrol
Description: Estetrol formulated in tablets, in escalating doses, will be investigated in patients with estrogen receptor positive (ER+) locally advanced or metastatic breast cancer.
Study NCT00971815 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: first week: 10mg/day. Then, treatment with 20mg/day is continued throughout a 3 months period of time.
Study NCT00971815 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1/2 pill pr day first week, then 1 pill pr. day throughout a 3 months treatment period (90-118 ± 7days)
Study NCT01364844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-7423
Description: oral capsule 1mg, 8mg, 48mg, and 80mg strengths administered once daily
Study NCT02124317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nanoparticle albumin-bound paclitaxel
Description: nanoparticle albumin-bound paclitaxel is given at 120 mg/m2 intravenously on day 1 and 8 of each 21 day cycle. Number of cycles: 6 cycles.
Study NCT02124317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1 is orally administered (40-60 mg according to the body surface, twice a day) on day 1-14 of each 21 day cycle. Number of cycles: 6 cycles.
Study NCT02795702 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Transcranial direct current stimulation
Study NCT02795702 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: Transcranial direct current stimulation
Study NCT02795702 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: training
Description: Cognitive training
Study NCT02795702 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: training
Description: Cognitive training
Study NCT02336217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Group instructions for glucose management via App
Description: The Experimental Group receives individually calculated instructions for glucose management management via the App.
Study NCT02336217 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator general instructions
Description: The Placebo Comparator Group receives general instructions but not the complete management algorithm
Study NCT04254172 — intervention group
Intervention type: DEVICE
Intervention: Activity Monitor
Description: Wrist and ankle sensors to be worn continuously for 2-week intervals.
Study NCT03792906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine 6 mcg
Description: An intravenous bolus of norepinephrine 6 mcg will be administered for management of maternal hypotension.
Study NCT03792906 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine 10 mcg
Description: An intravenous bolus of norepinephrine 10 mcg will be administered for management of maternal hypotension.